---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-21-028904"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2021-08-19T23:59:59+00:00"
generated_at: "2026-06-29T08:58:31.490178+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Director Kevin B. Churchwell resigns from Cyclerion board effective Aug 18, 2021

## Summary
- Kevin B. Churchwell, M.D. resigned from the board of directors on August 18, 2021.
- No disagreement with company operations, policies, or practices cited.
- Resignation due to expanded responsibilities as CEO of Boston Children's Hospital.
- Marsha Fanucci, Board Chair, thanked Churchwell for his service.

## SEC filing metadata
- accession: 0001140361-21-028904
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2021-08-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000114036121028904/0001140361-21-028904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000114036121028904/brhc10028200_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-21-028904
- JSON: https://secwatch.observer/filing/0001140361-21-028904.json
- Plain text: https://secwatch.observer/filing/0001140361-21-028904.txt

## Key facts
- Executive change
  Kevin B. Churchwell, M.D. resigned as Director at Cyclerion Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On and effective August 18, 2021, Kevin B. Churchwell, M.D., resigned from the board of directors of Cyclerion Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000114036121028904/0001140361-21-028904-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.